harm reduction – Medxy AI

Peer Support After Opioid Overdose: Randomized Trial Finds No Reduction in Future Adverse Events

By MedXY 02/11/2026

A randomized clinical trial of the Relay peer-navigator intervention in New York City found no significant reduction in opioid-related adverse events compared to standard care, despite high patient satisfaction and the intervention's grounding in evidence-based harm reduction principles.

Infectious Diseases news Public Health

Fentanyl and Xylazine Dominate the Illicit Supply: New Multi-City Data Reveal Deepening Polysubstance Crisis

By MedXY 02/10/2026

This toxicological analysis of out-of-treatment people who inject drugs across five major US cities found that 93% tested positive for fentanyl, while xylazine prevalence surged in the Northeast, underscoring the critical need for real-time drug surveillance and integrated harm-reduction strategies.

Oncology Psychiatry Specialties

Reducing Carcinogen Exposure in Smokers with Serious Mental Illness: Insights from a Randomized Controlled Trial of E-Cigarette Provision

By MedXY 08/25/2025

This RCT demonstrates that disposable e-cigarettes significantly reduce carcinogen levels short-term among smokers with serious mental illness, underscoring the need for behavioral support to sustain harm reduction.

Clinical Updates Medical News Psychiatry Specialties

Synthetic Opioid Overdose Deaths Among Youth Surge 168%: A Five-Year Analysis and Clinical Implications

By MedXY 07/29/2025

Overdose deaths from synthetic opioids alone in U.S. youth aged 15–24 surged 168% between 2018 and 2022, now representing one-third of all youth OD fatalities. Clinical vigilance, harm reduction, and targeted prevention are urgently needed.